Smith & Nephew Dermagraft Will Remain On OPPS Pass-Through List In 2004
This article was originally published in The Gray Sheet
Executive Summary
CMS is granting Smith & Nephew's request that its Dermagraft bio-engineered skin for treating hard-to-heal diabetic foot ulcers be kept on the transitional "pass-through" payment list through 2004, allowing at least two years of pass-through eligibility as a biologic
You may also be interested in...
Medicare Revisits “New Technology” Outpatient Payment Levels For 2002
FDG-PET will be reimbursed at $1,375 per procedure under CMS' hospital outpatient prospective payment system update for 2002. The payment rate will go into effect April 1
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.